✦ LIBER ✦

Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults

✍ Scribed by Markowitz, M.; Zolopa, A.; Squires, K.; Ruane, P.; Coakley, D.; Kearney, B.; Zhong, L.; Wulfsohn, M.; Miller, M. D.; Lee, W. A.

Book ID: 127334272
Publisher: Oxford University Press
Year: 2014
Tongue: English
Weight: 393 KB
Volume: 69
Category: Article
ISSN: 0305-7453
DOI: 10.1093/jac/dkt532

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety, Tolerability, and Pharmacokineti

Safety, Tolerability, and Pharmacokinetics of KP-1461 in Phase I Clinical Studies: A Single Oral Dose Study in Non-HIV-Infected Adults, and a 14-Day Dose-Escalating Study in Highly Antiretroviral-Experienced HIV-Infected Adults

✍ Clay, P. G.; McRae, M.; Laurent, J.-P. 📂 Article 📅 2011 🏛 SAGE Publications 🌐 English ⚖ 196 KB

Phase 2a Randomized Controlled Trial of

Phase 2a Randomized Controlled Trial of Short-Term Activity, Safety, and Pharmacokinetics of a Novel Nonnucleoside Reverse Transcriptase Inhibitor, RDEA806, in HIV-1-Positive, Antiretroviral-Naive Subjects

✍ Moyle, G.; Boffito, M.; Stoehr, A.; Rieger, A.; Shen, Z.; Manhard, K.; Sheedy, B 📂 Article 📅 2010 🏛 American Society for Microbiology 🌐 English ⚖ 618 KB

Switching to coformulated elvitegravir,

Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial

✍ Pozniak, Anton; Markowitz, Martin; Mills, Anthony; Stellbrink, Hans-Juergen; Ant 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 274 KB

A phase I trial of the pharmacokinetics,

A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infection

✍ Rachel W. Humphrey; Kathleen M. Wyvill; Bach-Yen Nguyen; Laura E. Shay; David R. 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 143 KB

ING116070: A Study of the Pharmacokineti

ING116070: A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in Cerebrospinal Fluid in HIV-1-Infected, Antiretroviral Therapy-Naive Subjects

✍ Letendre, S. L.; Mills, A. M.; Tashima, K. T.; Thomas, D. A.; Min, S. S.; Chen, 📂 Article 📅 2014 🏛 University of Chicago Press 🌐 English ⚖ 328 KB

A Switch in Therapy to a Reverse Transcr

A Switch in Therapy to a Reverse Transcriptase Inhibitor Sparing Combination of Lopinavir/Ritonavir and Raltegravir in Virologically Suppressed HIV-Infected Patients: A Pilot Randomized Trial to Assess Efficacy and Safety Profile: The KITE Study

✍ Ofotokun, Ighovwerha; Sheth, Anandi N.; Sanford, Sara E.; Easley, Kirk A.; Shenv 📂 Article 📅 2012 🏛 Mary Ann Liebert 🌐 English ⚖ 358 KB